Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Teva announces launch of Generic Campral® in the United States
Teva Pharmaceutical Industries Ltd., announced the launch of the generic equivalent to CAMPRAL®1 (acamprosate calcium) delayed-release tablets, 333 mg, in the United States. Acamprosate calcium delayed-release tablets are used for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at the start of treatment.
- Read more about Communicable diseases rise 32 perccent in 5 years, spending up 7 percent
Spending on programmes to control India’s three main communicable diseases malaria, tuberculosis and leprosy increased seven percent over five years while cases reported, taken together, increased 32 percent, according to an IndiaSpend analysis of government data.

[adsense:336x280:8701650588]
- Read more about Malaria first spread from birds: Study
Malaria, a life-threatening disease caused by parasites that are transmitted to people through mosquitoe bites, started out as a parasite in birds, and then it evolved to colonise bats, and from there it has evolved to affect other mammals, reveals a new study.
- Read more about New form of Ebola virus may cause disease in humans
The Reston virus, a member of the Ebola virus family which is known to circulate in domestic pigs in Asia, may acquire the few mutations necessary to cause disease in humans and to develop into a novel health threat, researchers have warned.
- Read more about Antibiotics before age two ups childhood obesity risk
Administration of three or more courses of antibiotics before a child reaches the age of two is linked to increased risk of early childhood obesity, says a new study.
- Read more about Endobroncial ultrasound can help in easy TB diagnosis
With the government announcing eradication of tuberculosis by 2030, a doctor has says a new 'Endobroncial Ultrasound' medical process that was introduced in India recently can contribute in faster diagnosis of the disease leading to correct treatment on time.
- Read more about Glenmark Pharmaceuticals receives tentative ANDA approval for Lacosamide Oral Solution, 10 mg/mL
Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for its Lacosamide Oral Solution, 10 mg/mL, the generic version of Vimpat® Oral Solution, 10 mg/mL of UCB, Inc. Glenmark will market this product upon receiving final approval of its Lacosamide Oral Solution, 10 mg/mL ANDA. The patent listed in the Orange Book for Vimpat® Oral Solution, 10 mg/mL is scheduled to expire on March 17, 2022.
- Read more about Aurobindo Pharma receives USFDA approval for Naproxen Sodium Tablets (OTC)
Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Naproxen Sodium Tablets USP, 220 mg (OTC). This product is expected to be launched in Q1 FY16-17.
- Read more about Albumedix drug delivery technology used by CSL behring to achieve 14 day dosing for Haemophilia B therapy
Albumedix announced that its albumin-based VELTIS® half-life extension technology is being used by CSL Behring in IDELVION®, a therapy recently authorized for the treatment of haemophilia B in the U.S. The application of Albumedix’s VELTIS technology in the drug delivers an extended half-life which will improve the lives of patients living with the condition by reducing the frequency of injections up to once every 14 days. The U.S. Centers for Disease Control and Prevention, report that the condition affects approximately one in 25,000 male births.
- Read more about Anacor Pharma announces FDA acceptance of NDA for Crisaborole Topical Ointment, 2%
Anacor Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review Anacor's New Drug Application (NDA) seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults.